Dr. Lori A. Gerard, MD

Dr. Gerard practices at Denver Endocrinology, Diabetes And Thyroid Center in Englewood, Colorado.

Dr. Gerard's NPI, 1720134331, was assigned on January 26, 2007. Dr. Gerard graduated from University of Colorado Anschutz Medical Campus in 2000. Dr. Gerard holds Colorado license 41674.

Dr. Gerard's primary practice is Denver Endocrinology, Diabetes and Thyroid Center, at 799 E Hampden Ave Suite 525 Suite 525, Englewood, CO 80113-2786. The practice phone is (303) 321-2644.

Dr. Gerard's primary practice is Denver Endocrinology, Diabetes And Thyroid Center in Englewood, Colorado. Dr. Gerard is also affiliated with HCA HealthONE Swedish. The medical group on file is Denver Endocrinology, Diabetes & Thyroid Center. Dmand AI also links Dr. Gerard to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gerard practices, 6 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Gerard's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Gerard is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dr. Gerard is licensed in Colorado.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, high cholesterol, hypercalcemia, osteoporosis, overactive thyroid and parathyroid gland disorder among the conditions Dr. Gerard treats.

CMS data shows 1,004 Medicare services from Dr. Gerard across 7 procedure codes in 2024, for 352 Medicare patients. Medicare paid $69,921 for them. Every service was in an office.

CMS counts 352 Medicare patients who saw Dr. Gerard in 2024. The largest group is 65 to 74, with 222 patients. 75% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gerard's median patient age at 57, with 76% women.

In 2024, Dr. Gerard wrote 1,678 Medicare Part D claims for 309 patients. 44% of them were for generic drugs. CMS names the drug for 1,414 of them, across 35 drugs with 11 or more claims each, at $424,423 in total drug cost. In 2023, CMS named 1,338 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Gerard for performance year 2024, reported as part of a group. Dr. Gerard accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gerard as offering telehealth.

Dmand AI links 3 papers to Dr. Gerard, published from 2006 to 2011. 2011 was the busiest year, with 2. Dr. Gerard's most frequent co-authors are Daniel H. Bessesen, MD, Kristin A. Harmon, MD and Linda A. Barbour, MD.

Dmand AI links Dr. Gerard to 3 clinical trials. Conditions studied include Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and Autoimmune Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Gerard that name 2 trials.

CMS Open Payments shows 128 general payments to Dr. Gerard from 9 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 85% of the total. Sanofi and Genzyme US Companies paid the most, $30,086. It also lists 3 research payments totaling $5,486 from 2018 to 2020, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Gerard, most recently CMS Stage 1 2012 in 2012.

Dr. Gerard graduated from University of Colorado Anschutz Medical Campus in 2000. Dr. Gerard is a member of AACE and ENDO.

Dr. Gerard is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.